Background Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) by May 31, 2021. After early reports of myocarditis during adverse events monitoring, the Israeli Ministry of Health initiated active surveillance. Methods We retrospectively reviewed data obtained from December 20, 2020, to May 31, 2021, regarding all cases of myocarditis and categorized the information using the Brighton Collaboration definition. We analyzed the occurrence of myocarditis by computing the risk difference for the comparison of the incidence after the first and second vaccine doses (21 days apart); by calculating the standardized incidence ratio of the observed-to-expected incidence within 21 days after the first dose and 30 days after the second dose, independent of certainty of diagnosis; and by calculating the rate ratio 30 days after the second dose as compared with unvaccinated persons. Results Among 304 persons with symptoms of myocarditis, 21 had received an alternative diagnosis. Of the remaining 283 cases, 142 occurred after receipt of the BNT162b2 vaccine; of these cases, 136 diagnoses were definitive or probable. The clinical presentation was judged to be mild in 129 recipients (95%); one fulminant case was fatal. The overall risk difference between the first and second doses was 1.76 per 100,000 persons (95% confidence interval [CI], 1.33 to 2.19), with the largest difference among male recipients between the ages of 16 and 19 years (difference, 13.73 per 100,000 persons; 95% CI, 8.11 to 19.46). As compared with the expected incidence based on historical data, the standardized incidence ratio was 5.34 (95% CI, 4.48 to 6.40) and was highest after the second dose in male recipients between the ages of 16 and 19 years (13.60; 95% CI, 9.30 to 19.20). The rate ratio 30 days after the second vaccine dose in fully vaccinated recipients, as compared with unvaccinated persons, was 2.35 (95% CI, 1.10 to 5.02); the rate ratio was again highest in male recipients between the ages of 16 and 19 years (8.96; 95% CI, 4.50 to 17.83), with a ratio of 1 in 6637. Conclusions The incidence of myocarditis, although low, increased after the receipt of the BNT162b2 vaccine, particularly after the second dose among young male recipients. The clinical presentation of myocarditis after vaccination was usually mild.
The exposure of the Earth’s surface to the energetic input of rainfall is one of the key factors controlling water erosion. While water erosion is identified as the most serious cause of soil degradation globally, global patterns of rainfall erosivity remain poorly quantified and estimates have large uncertainties. This hampers the implementation of effective soil degradation mitigation and restoration strategies. Quantifying rainfall erosivity is challenging as it requires high temporal resolution(<30 min) and high fidelity rainfall recordings. We present the results of an extensive global data collection effort whereby we estimated rainfall erosivity for 3,625 stations covering 63 countries. This first ever Global Rainfall Erosivity Database was used to develop a global erosivity map at 30 arc-seconds(~1 km) based on a Gaussian Process Regression(GPR). Globally, the mean rainfall erosivity was estimated to be 2,190 MJ mm ha−1 h−1 yr−1, with the highest values in South America and the Caribbean countries, Central east Africa and South east Asia. The lowest values are mainly found in Canada, the Russian Federation, Northern Europe, Northern Africa and the Middle East. The tropical climate zone has the highest mean rainfall erosivity followed by the temperate whereas the lowest mean was estimated in the cold climate zone.
During the 13 years from 1990 to 2002, the prevalence of myopia significantly increased among the Israeli population. Although there was an association with the level of education, gender, ethnicity, and origin, the prevalence of myopia increased on an annual basis, independent of these factors.
An evaluation of 23 models, participating in the Coupled Model Inter‐comparison Project phase 5 (CMIP5), in representing extreme precipitation indices (EPI), over the Eastern Mediterranean (EM) and the Fertile Crescent (FC), was performed. The models ensemble was then used to predict the EPIs evolution in the 21st century under (Representative Concentration Pathway, RCP) RCP4.5 and RCP8.5 scenarios. Models' performance was determined with respect to gridded precipitation observations from the APHRODITE project. The ensemble mean was found to perform relatively well in capturing the EM steep precipitation gradient, the FC structure and the EPI trends in the observations period (1970–2000). Over the EM, CMIP5 models agree on a future decrease in the following three EPIs; total precipitation (TP), consecutive wet days, and number of wet days by the values of 20–35%, 10–20%, and 20–35%, respectively. In the FC, extremely wet days (P95) are expected to increase by approximately 25%, except for the south eastern coasts of the Mediterranean Sea, which show significant decreases in P95, particularly for RCP8.5 and at the end of the 21st century. Hence, while TP is expected to decrease, extreme precipitation is expected to increase, at least for the north‐eastern part of the FC. This will significantly influence agriculture and floods' potential in a region already suffering from political unrest. The changes in EPIs are related to changes in the synoptic patterns over the EM, especially the predicted changes in cyclones frequency and intensity in the 21st century, due to changes in storm tracks governed by the phase of the North Atlantic Oscillation and the expected expansion of the Hadley Cell towards the poles in a warmer climate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.